Arena Pharmaceuticals (FRA:RN3N) Total Stockholders Equity : €595.82 Mil (As of Dec. 2021)

View and export this data going back to 2000. Start your Free Trial

What is Arena Pharmaceuticals Total Stockholders Equity?

Arena Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Dec. 2021 was €595.82 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Arena Pharmaceuticals's Book Value per Share for the quarter that ended in Dec. 2021 was €9.68. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Arena Pharmaceuticals's Debt-to-Equity for the quarter that ended in Dec. 2021 was 0.06.

Arena Pharmaceuticals Total Stockholders Equity Historical Data

The historical data trend for Arena Pharmaceuticals's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arena Pharmaceuticals Total Stockholders Equity Chart

Arena Pharmaceuticals Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Total Stockholders Equity

Get a 7-Day Free Trial

175.04

532.90

964.32

888.15

595.82

Arena Pharmaceuticals Quarterly Data
	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21
Total Stockholders Equity	Get a 7-Day Free Trial															888.15	912.23	806.00	680.61	595.82

Arena Pharmaceuticals (FRA:RN3N) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Arena Pharmaceuticals's Book Value per Share for the quarter that ended in Dec. 2021 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(595.815	-	0)	/	61.5641
	=	9.68

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Arena Pharmaceuticals's Debt-to-Equity for the quarter that ended in Dec. 2021 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(4.471	+	32.001)	/	595.815
	=	0.06

Arena Pharmaceuticals Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Arena Pharmaceuticals's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Arena Pharmaceuticals (FRA:RN3N) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arena Pharmaceuticals Inc (FRA:RN3N) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

136 Heber Avenue, Suite 204, Park City, UT, USA, 84060

Website

https://www.arenapharm.com

Arena Pharmaceuticals is a biotechnology company targeting G-protein-coupled receptors. The company has one internally discovered drug, lorcaserin, which has been approved and is marketed in the U.S. and South Korea to target weight management. It is commercialized under the brand name Belviq. The company is collaborating with Eisai to market Belviq in other countries. It has a presence in Europe through its Swiss subsidiary, Arena GmbH. The company's pipeline contains drugs targeting autoimmune diseases, vascular diseases, thrombotic diseases, dementia-associated psychosis, nervous system issues, and pain.

Arena Pharmaceuticals (FRA:RN3N) Headlines

No Headlines